Cargando…

Mechanisms of immune effector cell‐associated neurotoxicity syndrome after CAR‐T treatment

Chimeric antigen receptor T‐cell (CAR‐T) treatment has revolutionized the landscape of cancer therapy with significant efficacy on hematologic malignancy, especially in relapsed and refractory B cell malignancies. However, unexpected serious toxicities such as cytokine release syndrome (CRS) and imm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Tianning, Hu, Kejia, Si, Xiaohui, Hu, Yongxian, Huang, He
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Advanced Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787013/ https://www.ncbi.nlm.nih.gov/pubmed/35871757 http://dx.doi.org/10.1002/wsbm.1576

Ejemplares similares

Inhibition of Calcium Signaling Prevents Exhaustion and Enhances Anti‐Leukemia Efficacy of CAR‐T Cells via SOCE‐Calcineurin‐NFAT and Glycolysis Pathways
por: Shao, Mi, et al.
Publicado: (2022)

Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting
por: Wang, Ji-nuo, et al.
Publicado: (2022)

EEG-based grading of immune effector cell-associated neurotoxicity syndrome
por: Jones, Daniel K., et al.
Publicado: (2022)

Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy
por: Amidi, Yalda, et al.
Publicado: (2022)

Nanoscale CAR Organization at the Immune Synapse Correlates with CAR-T Effector Functions
por: Sajman, Julia, et al.
Publicado: (2023)

Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
por: Xiao, Xinyi, et al.
Publicado: (2021)

Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS)
por: Saw, Jacqui-Lyn, et al.
Publicado: (2022)

Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
por: Sterner, Robert C., et al.
Publicado: (2022)

A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome
por: Butt, Omar H., et al.
Publicado: (2023)

Automated detection of immune effector cell‐associated neurotoxicity syndrome via quantitative EEG
por: Eckhardt, Christine A., et al.
Publicado: (2023)

Cytokines in CAR T Cell–Associated Neurotoxicity
por: Gust, Juliane, et al.
Publicado: (2020)

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2018)

Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy
por: Ferreros, Puri, et al.
Publicado: (2022)

Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy
por: Tang, Jack Pengfei, et al.
Publicado: (2022)

Cytokine Release Syndrome Is an Independent Risk Factor Associated With Platelet Transfusion Refractoriness After CAR-T Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
por: Liu, Yadan, et al.
Publicado: (2021)

Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)
por: Wehrli, Marc, et al.
Publicado: (2022)

This CAR won’t start: predicting nonresponse in ALL
por: Webster, Jonathan A., et al.
Publicado: (2023)

P1401: IDENTIFICATION OF BIOMARKERS AND RISK FACTORS FOR IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) IN CD19-DIRECTED CAR T-CELL THERAPY: A RETROSPECTIVE MACHINE LEARNING-BASED ANALYSIS.
por: Gómez-Llobell, Marina, et al.
Publicado: (2023)

Single-cell transcriptome analysis and protein profiling reveal broad immune system activation in IgG4-related disease
por: Lu, Chenyang, et al.
Publicado: (2023)

An efficient method to clone TAL effector genes from Xanthomonas oryzae using Gibson assembly
por: Li, Chenhao, et al.
Publicado: (2019)

Novel pathophysiological insights into CAR-T cell associated neurotoxicity
por: Genoud, Vassilis, et al.
Publicado: (2023)

Editorial: Novel insights into CAR T-cell associated neurotoxicity
por: Bouziana, Stella
Publicado: (2023)

Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment
por: Schoeberl, Florian, et al.
Publicado: (2022)

Comorbidities in DLBCL: too "Severe4" CAR-T therapy?
por: Qualls, David, et al.
Publicado: (2023)

Immune Effector Cell Associated Neurotoxicity (ICANS) in Pediatric and Young Adult Patients Following Chimeric Antigen Receptor (CAR) T-Cell Therapy: Can We Optimize Early Diagnosis?
por: Brown, Brandon Douglas, et al.
Publicado: (2021)

Efficient disruption and replacement of an effector gene in the oomycete P hytophthora sojae using CRISPR/Cas9
por: Fang, Yufeng, et al.
Publicado: (2015)

A library of synthetic transcription activator-like effector-activated promoters for coordinated orthogonal gene expression in plants
por: Brückner, Kathleen, et al.
Publicado: (2015)

Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma
por: Castaneda-Puglianini, Omar, et al.
Publicado: (2021)

It Is in the Eye of the Beholder: Ocular Ultrasound Enhanced Monitoring of Neurotoxicity after CAR-T Cell Therapy
por: Garcia-Robledo, Juan Esteban, et al.
Publicado: (2022)

CAR trafficking does matter: prospects of ‘Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy’
por: Li, Wentao, et al.
Publicado: (2020)

CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
por: Fu, Wenyan, et al.
Publicado: (2019)

Applying (or Not?) CAR-T Neurotoxicity Experience to COVID-19 Delirium and Agitation
por: Mack, Avram H., et al.
Publicado: (2020)

Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam
por: Xiong, Luying, et al.
Publicado: (2022)

Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy
por: Ding, Shuyi, et al.
Publicado: (2023)

Pomalidomide-based regimens bridging CAR-T therapy in multiple myeloma with central nervous system involvement
por: Zhang, Qiqi, et al.
Publicado: (2022)

On a collision course: SARS-CoV-2 variants and CAR T cells
por: Auletta, Jeffery J.
Publicado: (2023)

Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells
por: Karschnia, Philipp, et al.
Publicado: (2021)

Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell–Associated Neurotoxicity Syndrome
por: Butt, Omar H., et al.
Publicado: (2022)

Description of neurotoxicity in a series of patients treated with CAR T-cell therapy
por: Belin, Catherine, et al.
Publicado: (2020)

Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity
por: Sokolov, Elisaveta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o0qmu7agl2qs7qpgqe9pnjcmnd